Nahdi Medical Company (4164.SR)
SAR 114.0
(0.35%)
SAR 114.0
(0.35%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 8.71 Billion SAR | 1.13% |
| 2022 | 8.61 Billion SAR | 6.82% |
| 2021 | 8.06 Billion SAR | -6.66% |
| 2020 | 8.64 Billion SAR | 10.45% |
| 2019 | 7.82 Billion SAR | 6.46% |
| 2018 | 7.35 Billion SAR | 4.16% |
| 2017 | 7.05 Billion SAR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 2.25 Billion SAR | 1.95% |
| 2024 Q3 | 2.35 Billion SAR | -4.83% |
| 2024 Q2 | 2.47 Billion SAR | 9.53% |
| 2023 Q4 | 2.21 Billion SAR | 2.37% |
| 2023 FY | 8.71 Billion SAR | 1.13% |
| 2023 Q3 | 2.16 Billion SAR | -3.07% |
| 2023 Q2 | 2.23 Billion SAR | 6.01% |
| 2023 Q1 | 2.1 Billion SAR | -1.55% |
| 2022 Q2 | 2.23 Billion SAR | 7.69% |
| 2022 Q1 | 2.07 Billion SAR | 5.39% |
| 2022 Q3 | 2.15 Billion SAR | -3.59% |
| 2022 FY | 8.61 Billion SAR | 6.82% |
| 2022 Q4 | 2.13 Billion SAR | -0.96% |
| 2021 FY | 8.06 Billion SAR | -6.66% |
| 2021 Q4 | 1.97 Billion SAR | -3.36% |
| 2021 Q3 | 2.04 Billion SAR | -1.37% |
| 2021 Q2 | 2.07 Billion SAR | 4.49% |
| 2021 Q1 | 1.98 Billion SAR | -0.25% |
| 2020 Q1 | 2.26 Billion SAR | 0.0% |
| 2020 FY | 8.64 Billion SAR | 10.45% |
| 2020 Q4 | 1.98 Billion SAR | -7.0% |
| 2020 Q3 | 2.13 Billion SAR | -11.88% |
| 2020 Q2 | 2.42 Billion SAR | 7.23% |
| 2019 FY | 7.82 Billion SAR | 6.46% |
| 2018 FY | 7.35 Billion SAR | 4.16% |
| 2017 FY | 7.05 Billion SAR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Middle East Pharmaceutical Industries Co. | 338.43 Million SAR | -2474.661% |
| Al-Dawaa Medical Services Company | 5.74 Billion SAR | -51.77% |
| Al-Razi Medical Co. | 61.33 Million SAR | -14106.965% |
| Almujtama Alraida Medical Co. | 407.73 Million SAR | -2037.069% |